http://www.mmm-online.com Latest articles from Medical Marketing and Media Business Briefs MMM Business Briefs The latest account wins and other short business stories from the healthcare marketing and communications sector. Business Briefs mmmsubs@haymarketmedia.com no Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement. http://www.mmm-online.com/business-briefs-merck-and-forest-labs/article/294660/ Thu, 23 May 2013 18:27:46 GMT Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement. MMM Pfizer seeks full Zoetis split, Novartis gets another NICE Lucentis indication, BI tussles with the FDA and Elsevier names a Cleveland Clinic doc EIC http://www.mmm-online.com/business-briefs-pfizer-novartis-boehringer-ingelheim-elsevier/article/294393/ Wed, 22 May 2013 15:46:35 GMT Pfizer seeks full Zoetis split, Novartis gets another NICE Lucentis indication, BI tussles with the FDA and Elsevier names a Cleveland Clinic doc EIC MMM inVentiv adds new comms exec; Julie Bowen teams up with Mylan for allergy emergencies; Royalty raises the bid on Elan; Pfizer nixes non-Hodgkin's lymphoma drug in trials. http://www.mmm-online.com/business-briefs-inventiv-mylan-royalty-pharma-pfizer-edelman/article/294294/ Tue, 21 May 2013 17:52:16 GMT inVentiv adds new comms exec; Julie Bowen teams up with Mylan for allergy emergencies; Royalty raises the bid on Elan; Pfizer nixes non-Hodgkin's lymphoma drug in trials. MMM Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M http://www.mmm-online.com/business-briefs-actavis-bayer-oramed-elan/article/294031/ Mon, 20 May 2013 16:12:27 GMT Actavis buys Warner Chilcott, FDA clears oral insulin for testing, Elan swallows AOP Orphan for $340M MMM Pfizer cuts 136 workers loose in Ireland, BMS is investing in heart failure treatments, CMS has an official new leader, and Sanofi's iBGStar may have a competitor. http://www.mmm-online.com/business-briefs-pfizer-bms-cms-sanofi/article/293671/ Thu, 16 May 2013 16:50:50 GMT Pfizer cuts 136 workers loose in Ireland, BMS is investing in heart failure treatments, CMS has an official new leader, and Sanofi's iBGStar may have a competitor. MMM Bayer's prostate cancer drug clears FDA three months early; a House committee is pressing the regulator for employment transparancy; and Ranbaxy takes a multi-million dollar hit over violations http://www.mmm-online.com/business-briefs-bayer-fda-ranbaxy/article/293533/ Wed, 15 May 2013 19:13:18 GMT Bayer's prostate cancer drug clears FDA three months early; a House committee is pressing the regulator for employment transparancy; and Ranbaxy takes a multi-million dollar hit over violations MMM Jolie takes on cancer awareness role, researchers identify another adherence gap, Sanofi gets slapped for scare tactics, Teva may compete for Adcock, AbbVie R&D chief leaves http://www.mmm-online.com/business-briefs-angelina-jolie-adherence-sanofi-teva-abbvie/article/293341/ Tue, 14 May 2013 18:54:50 GMT Jolie takes on cancer awareness role, researchers identify another adherence gap, Sanofi gets slapped for scare tactics, Teva may compete for Adcock, AbbVie R&D chief leaves MMM Eli Lilly nixes one trial and fails another; Millennium is folded into Takeda, Dunsire retires; Elan pays for Theravance royalties in attempt to avoid takeover. http://www.mmm-online.com/business-briefs-eli-lilly-millenniumtakeda-elan/article/293158/ Mon, 13 May 2013 15:07:40 GMT Eli Lilly nixes one trial and fails another; Millennium is folded into Takeda, Dunsire retires; Elan pays for Theravance royalties in attempt to avoid takeover. MMM HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets. http://www.mmm-online.com/business-briefs-merck-gsk-novo-walgreen-epocrates-doximity/article/292622/ Thu, 09 May 2013 14:56:06 GMT HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets. MMM Arena gets closer to the market place, Takeda scoops up privately held Inviragen, Plan B court decision is coming and Cubist antibotic lands breakthrough therapy status. http://www.mmm-online.com/business-briefs-arena-takeda-teva-cubist/article/292521/ Wed, 08 May 2013 17:05:17 GMT Arena gets closer to the market place, Takeda scoops up privately held Inviragen, Plan B court decision is coming and Cubist antibotic lands breakthrough therapy status. MMM Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV. http://www.mmm-online.com/business-briefs-baxter-eli-lilly-cdhps-and-statins/article/292338/ Tue, 07 May 2013 16:42:12 GMT Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV. MMM Pfizer's online Viagra deal with CVS; reorg at the EMA; Mills moves up at Digitas http://www.mmm-online.com/business-briefs-pfizer-and-cvs-the-ema-digitas-health-new-york/article/292169/ Mon, 06 May 2013 19:40:21 GMT Pfizer's online Viagra deal with CVS; reorg at the EMA; Mills moves up at Digitas MMM Lantus cushions Sanofi's quarterly sales; Allergan holds back on Eylea competitor; FDA limits use of Otsuka drug; Genmab lands Breakthrough label; NIH finds a link among cancers; and Novartis offers lunch with a side of medical information; DOJ appeals Plan-B Ruling. http://www.mmm-online.com/business-briefs-sanofi-allergan-otsuka-genmab-nih-novartis-doj/article/291724/ Thu, 02 May 2013 16:33:13 GMT Lantus cushions Sanofi's quarterly sales; Allergan holds back on Eylea competitor; FDA limits use of Otsuka drug; Genmab lands Breakthrough label; NIH finds a link among cancers; and Novartis offers lunch with a side of medical information; DOJ appeals Plan-B Ruling. MMM FDA lowers Teva's Plan B age limit to 15; CSL Behring's anticoagulant gets approval; Pradaxa gets slapped with black box for stroke risks; Mylan recruits former FDA deputy comissioner; Amgen's Neulasta and Neupogen drugs could save you in a nuclear apocalypse. http://www.mmm-online.com/business-briefs-teva-vertex-csl-behring-boehringer-mylan-amgen/article/291550/ Wed, 01 May 2013 16:32:07 GMT FDA lowers Teva's Plan B age limit to 15; CSL Behring's anticoagulant gets approval; Pradaxa gets slapped with black box for stroke risks; Mylan recruits former FDA deputy comissioner; Amgen's Neulasta and Neupogen drugs could save you in a nuclear apocalypse. MMM Health-seeking consumers continue social-media push; Scioderm scores FDA's "Breakthrough" designation for bullosa agent; and GSK files NDA for airway treatment. http://www.mmm-online.com/business-briefs-manhattan-research-kpmg-scioderm-and-gsk/article/291222/ Tue, 30 Apr 2013 16:48:24 GMT Health-seeking consumers continue social-media push; Scioderm scores FDA's "Breakthrough" designation for bullosa agent; and GSK files NDA for airway treatment. MMM Merck and Pfizer partner up for an SGLT2 for diabetes; Bayer acquires contraceptive maker; Valeant and Actavis merger negotiations are put on hold; Gilead's HIV combo drug receives regulator setback. http://www.mmm-online.com/business-briefs-merck-and-pfizer-valeant-and-actavis-bayer-gilead/article/291048/ Mon, 29 Apr 2013 18:09:32 GMT Merck and Pfizer partner up for an SGLT2 for diabetes; Bayer acquires contraceptive maker; Valeant and Actavis merger negotiations are put on hold; Gilead's HIV combo drug receives regulator setback. MMM Doctors call out Novartis on drug prices; Aubagio shows strong top-line data in trials; and overseas docs increasingly turn to digital. http://www.mmm-online.com/business-briefs-docs-question-gleevec-price-sanofi-pill-may-delay-ms-onset/article/290560/ Thu, 25 Apr 2013 17:17:27 GMT Doctors call out Novartis on drug prices; Aubagio shows strong top-line data in trials; and overseas docs increasingly turn to digital. MMM Merck's experimental skin cancer drug gets breakthrough status; Tavenner's nod hits a roadblock; study shows biotechs aren't doing enough to please payers; and Sucampo's Amitiza gains a new indication. http://www.mmm-online.com/business-briefs-merck-cms-and-sucampo/article/290302/ Wed, 24 Apr 2013 15:43:33 GMT Merck's experimental skin cancer drug gets breakthrough status; Tavenner's nod hits a roadblock; study shows biotechs aren't doing enough to please payers; and Sucampo's Amitiza gains a new indication. MMM Roche is shuttering a division and eliminating 170 jobs; Doximity has added another client; a cautiously-worded study indicates antidepressants may be linked to autism; and NICE has endorsed a new use for Bayer's Xarelto. http://www.mmm-online.com/business-briefs-roche-doximity-and-bayer/article/290194/ Tue, 23 Apr 2013 17:43:17 GMT Roche is shuttering a division and eliminating 170 jobs; Doximity has added another client; a cautiously-worded study indicates antidepressants may be linked to autism; and NICE has endorsed a new use for Bayer's Xarelto. MMM GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment. http://www.mmm-online.com/business-briefs-gsk-astellas-vertex-and-orexigen/article/289879/ Mon, 22 Apr 2013 16:19:10 GMT GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment. MMM